RHEINBREITBACH, Germany, October 8, 2018 /PRNewswire/ --
Jennewein Biotechnologie GmbH announces that it has acquiredthe former facilities of Arthus Mineralspring Company in Bad Hönningen (Rhineland-Palatine) in order to expand the production of human milk oligosaccharides (HMOs). "We have been searching for some time for a suitable location to establish an integrated
About Jennewein Biotechnologie: Jennewein Biotechnologie is a leading international industrial biotechnology company with a range of products in the field of complex oligosaccharides (HMOs) and rare monosaccharides. The company manufactures an extensive portfolio of innovative HMO products, such as 2?-fucosyllactose, 3?-fucosyllactose and lacto-N-tetraose. These rare sugars are used in the food industry (particularly infant milk formulas), the pharmaceutical industry, and the cosmetic industry. The manufacturing process involves state-of-the-art fermentation techniques. In 2015, the US Food and Drug Administration (FDA) granted Jennewein Biotechnologie a license to market 2?-fucosyllactose in the USA. This was followed in 2017 by European Union marketing authorisation under the Novel Food Regulation.
Press contact: Dr. Bettina Gutierrez firstname.lastname@example.org +49-02224/98810797
SOURCE Jennewein Biotechnologie GmbH
Subscribe to our Free Newsletters!